首页|枸地氯雷他定对慢性荨麻疹的治疗效果及安全性评价

枸地氯雷他定对慢性荨麻疹的治疗效果及安全性评价

扫码查看
目的 分析针对慢性荨麻疹(Chronic Urticaria,CU)患者采用枸地氯雷他定药物治疗的疗效与安全性.方法 选取2022年1月—2023年2月连云港市赣榆区人民医院收治的100例CU患者为研究对象,根据随机数表法分为两组,参照组(n=50)口服氯雷他定片,观察组(n=50)口服枸地氯雷他定片.对比两组患者炎症因子水平、治疗效果、慢性荨麻疹症状积分、药物不良反应发生率.结果 治疗4周后,观察组免疫球蛋白E(Immu-noglobulin E,IgE)、白细胞介素-23(Interleukin-23,IL-23)、肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)水平分别为(92.24±7.93)U/mL、(25.36±2.94)ng/L、(20.26±3.67)ng/L,低于参照组的(115.95±13.68)IU/mL、(30.98±3.81)ng/L、(26.45±4.71)ng/L,差异有统计学意义(t=10.603、8.258、7.330,P均<0.05);观察组治疗总有效率为94.00%,高于参照组的78.00%,差异有统计学意义(χ2=5.316,P<0.05);观察组CU症状积分低于参照组,差异有统计学意义(P<0.05);观察组药物不良反应发生率为6.00%,较参照组的22.00%更低,差异有统计学意义(χ2=5.316,P<0.05);观察组发作次数少于参照组,且风团持续时间短于参照组,差异有统计学意义(P均<0.05).结论 枸地氯雷他定治疗CU,能够改善患者临床症状,降低炎症因子水平及不良反应发生率,提升治疗效果,减少发作次数及风团持续时间.
Efficacy and Safety Evaluation of Desloratadine Citrate in the Treatment of Chronic Urticaria
Objective To analyze the efficacy and safety of desloratadine citrate in the treatment of chronic urticaria(CU).Methods A total of 100 patients with CU admitted to Ganyu District People's Hospital of Lianyungang City from January 2022 to February 2023 were selected as the study objects and divided into two groups according to random number table method.The reference group(n=50)was given loratadine orally,and the observation group(n=50)was given deloratadine orally.The levels of inflammatory factors,therapeutic effect,symptom score of chronic urticaria,in-cidence of adverse drug reactions and coagulation index were compared between the two groups of patients.Results After 4 weeks of treatment,immunoglobulin E(IgE),interleukin-23(IL-23)and tumor necrosis factor-α(TNF-α)lev-els in the observation group were(92.24±7.93)U/mL,(25.36±2.94)ng/L and(20.26±3.67)ng/L,respectively,and lower than(115.95±13.68)U/mL,(30.98±3.81)ng/L and(26.45±4.71)ng/L in the reference group,and the differences were statistically significant(t=10.603,8.258,7.330,all P<0.05).The total effective rate of observation group was 94.00%,which was higher than that of reference group(78.00%),and the difference was statistically significant(χ2= 5.316,P<0.05).The CU symptom score of observation group was lower than that of reference group,and the difference was statistically significant(P<0.05).The incidence of adverse drug reactions in observation group was 6.00%,which was lower than that in reference group(22.00%),and the difference was statistically significant(χ2=5.316,P<0.05).The frequency of attack in observation group was less than that in reference group,and the duration of wind cluster was shorter than that in reference group,and the difference was statistically significant(both P<0.05).Conclusion In the treatment of CU,deloratadine citrate can improve the clinical symptoms of patients,reduce the level of inflamma-tory factors and the incidence of adverse reactions,improve the therapeutic effect,reduce the number of attacks and the duration of wind mass.

Chronic urticariaLoratadine tabletsDesloratadine citrateAdverse reaction

王焕玲、程伟、韦艳芹、王于斌

展开 >

连云港市赣榆区人民医院皮肤性病科,江苏连云港 222000

慢性荨麻疹 氯雷他定片 枸地氯雷他定 不良反应

2024

系统医学

系统医学

ISSN:
年,卷(期):2024.9(1)
  • 20